A Palmitoylethanolamide Producing Lactobacillus paracasei Improves Clostridium difficile Toxin A-Induced Colitis

Area of Science:

• Microbiology
• Gastroenterology
• Biotechnology

Background:

• Clostridium difficile infection (CDI) poses a significant therapeutic challenge.
• Genetically engineered probiotics offer a novel strategy for localized drug delivery and gut eubiosis restoration.
• Palmitoylethanolamide (PEA) exhibits anti-inflammatory and barrier-protective properties relevant to colitis.

Purpose of the Study:

• To evaluate the therapeutic efficacy of a novel PEA-producing probiotic (pNAPE-LP) in a mouse model of CDI.
• To investigate the mechanisms underlying the protective effects of pNAPE-LP, focusing on inflammation and epithelial barrier function.

Main Methods:

• Engineered Lactobacillus paracasei (pNAPE-LP) to express N-acyl-phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) for PEA synthesis.
• Administered pNAPE-LP intragastrically to mice prior to induction of colitis with Clostridium difficile toxin A (TcdA).
• Assessed colitis severity, inflammatory markers, and tight junction protein expression in treated mice compared to controls.

Main Results:

• pNAPE-LP significantly increased PEA production in vivo.
• Treatment with pNAPE-LP markedly reduced histological damage, inflammatory cell infiltration, and key inflammatory mediators (e.g., IL-6, TNF-α).
• pNAPE-LP treatment restored epithelial barrier integrity by upregulating tight junction proteins (e.g., ZO-1, occludin).

Conclusions:

• Engineered probiotics delivering PEA demonstrate significant therapeutic potential for CDI.
• This approach effectively inhibits colonic inflammation and restores gut barrier function in a preclinical model.
• Next-generation probiotics represent a promising strategy for the prevention and treatment of CDI.